Rebeca Rodriguez-Veiga (Rebeca Rodríguez-Veiga)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 11

Top Topics

Monoclonal Antibody

Acute Myeloid Leukemia

Disease Activity

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Blood cancer journal

Disease markers

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Esperanza Martin-Sanchez, Laura Blanco-Fernández, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesús San F Miguel, Ana Alfonso, Juan-Miguel Bergua, Rebeca Rodriguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Juan José Lahuerta, Aintzane Zabaleta
Targeting CD38 by isatuximab and a CD38/CD3xCD28 trispecific T-cell engager in old patients with acute myeloid leukemia. Blood advances (2024)
Esperanza Martin-Sanchez, Laura Blanco-Fernández, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesús San F Miguel, Ana Alfonso, Juan-Miguel Bergua, Rebeca Rodriguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Juan José Lahuerta, Aintzane Zabaleta
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia. Blood advances 8 (15) (2024)
Esperanza Martin-Sanchez, Laura Blanco-Fernández, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesús San F Miguel, Ana Alfonso, Juan-Miguel Bergua, Rebeca Rodriguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Juan José Lahuerta, Aintzane Zabaleta
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia. Blood advances 8 (15) (2024)
Esperanza Martin-Sanchez, Laura Blanco-Fernández, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesús San F Miguel, Ana Alfonso, Juan-Miguel Bergua, Rebeca Rodriguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Juan José Lahuerta, Aintzane Zabaleta
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia. Blood advances 8 (15) (2024)
Antonio Solana-Altabella, Rebeca Rodriguez-Veiga, David Martínez-Cuadrón, Pau Montesinos
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold? Annals of hematology (2024)
Claudia Sargas, Rosa María Ayala, María J Larráyoz, María C Chillón, Eduardo Rodríguez Arbolí, Cristina Bilbao, Esther Prados de la Torre, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, Blanca Boluda, Cristina Gil, Teresa Bernal, Juan-Miguel Bergua, Lorenzo Algarra, María Del Mar Tormo Díaz, Pilar Martínez-Sánchez, Elena Soria, Josefina Serrano, Juan Manuel Alonso-Domínguez, Raimundo García, María Luz Amigo, Pilar Herrera-Puente, María J Sayas, Esperanza Lavilla-Rubira, Joaquín Martínez-López, María-José Calasanz, Miriam Santero, José Antonio Pérez-Simón, María T Gómez Casares, Joaquín Sánchez-García, Eva Barragán, Pau Montesinos, null null
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood cancer journal 13 (1) (2023)
Claudia Sargas, Rosa María Ayala, María J Larráyoz, María C Chillón, Eduardo Rodríguez Arbolí, Cristina Bilbao, Esther Prados de la Torre, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, Blanca Boluda, Cristina Gil, Teresa Bernal, Juan-Miguel Bergua, Lorenzo Algarra, María Del Mar Tormo Díaz, Pilar Martínez-Sánchez, Elena Soria, Josefina Serrano, Juan Manuel Alonso-Domínguez, Raimundo García, María Luz Amigo, Pilar Herrera-Puente, María J Sayas, Esperanza Lavilla-Rubira, Joaquín Martínez-López, María-José Calasanz, Miriam Santero, José Antonio Pérez-Simón, María T Gómez Casares, Joaquín Sánchez-García, Eva Barragán, Pau Montesinos, null null
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood cancer journal 13 (1) (2023)
Tamara Castaño-Bonilla, Eva Barragán, Claudia Sargas, Alejandro Sanz, Lorenzo Algarra, Pilar Herrera-Puente, Raimundo García-Boyero, Manuel Barrios, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, Blanca Boluda, Cristina Gil, Josefina Serrano-López, Joaquin Martinez Lopez, María José Sayas-Lloris, María Teresa Olave, Rosalía Riaza-Grau, Teresa Bernal-Del Castillo, María José Larráyoz, Raquel Amigo, Antonio Jiménez-Velasco, Joaquín Sánchez, Rosa María Ayala, Carlos Blas López, Daniel Lainez-González, Juana Serrano-López, Miguel Angel Sanz, Juan Manuel Alonso-Domínguez, Pau Montesinos
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group. Disease markers 2022 (2022)
Blanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, Isabel Cano, María J Sayas, Evelyn Acuña-Cruz, Albert Blanco, Javier Marco-Ayala, Rosalía DeLapuerta, Álvaro Díaz-González, María Del Mar Tormo Díaz, Rebeca Rodriguez-Veiga, Raimundo García, José Luis Piñana, María López-Pavía, Eva Barragán, María L Amigo, Claudia Sargas, Aurelio López, Antonio Solana-Altabella, Cristina Gil, Juan Eduardo Megías-Vericat, Miguel Angel Sanz, Pau Montesinos
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. Leukemia & lymphoma 62 (11) (2021)
David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, Mar Tormo, Pilar Martínez-Sánchez, José A Pérez-Simón, Raimundo García-Boyero, Carlos Rodríguez-Medina, María López-Pavía, Celina Benavente, Juan-Miguel Bergua, Esperanza Lavilla-Rubira, María-Luz Amigo, Pilar Herrera, Juan Manuel Alonso-Domínguez, Teresa Bernal Del Castillo, Mercedes Colorado, María J Sayas, Lorenzo Algarra, Maria Vidriales Vicente, Gabriela Rodríguez-Macías, Susana Vives, Manuel Mateo Pérez Encinas, Aurelio López, Víctor Noriega, María García-Fortes, Fernando Ramos, Juan I Rodríguez-Gutiérrez, Lisette Costilla-Barriga, Jorge Labrador, Blanca Boluda, Rebeca Rodriguez-Veiga, Joaquin Martinez Lopez, Miguel Angel Sanz, Pau Montesinos
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia 35 (6) (2020)
Juan M Bergua, Pau Montesinos, David Martinez-Cuadrón, Pascual Fernández-Abellán, Josefina Serrano, María J Sayas, Julio Prieto-Fernandez, Raimundo García, Ana J García-Huerta, Manuel Barrios, Celina Benavente, Manuel Pérez-Encinas, Adriana Simiele, Gabriela Rodríguez-Macias, Pilar Herrera-Puente, Rebeca Rodriguez-Veiga, María P Martínez-Sánchez, María L Amador-Barciela, Rosalía Riaza-Grau, Miguel A Sanz, null null
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. British journal of haematology 174 (5) (2016)